Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.
Response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Italy: a 3-month follow-up.
复制标题
DOI：
10.1007/s11739-021-02857-y
复制
发表时间：
2022-03
影响因子：
4.6
通讯作者：
Mantovani LG
中科院分区：
文献类型：
--
作者：
Ponticelli D;Madotto F;Conti S;Antonazzo IC;Vitale A;Della Ragione G;Romano ML;Borrelli M;Schiavone B;Polosa R;Ferrara P;Mantovani LG
本研究调查了意大利一家教学医院医护人员对BNT162b2mRNA新冠肺炎疫苗的反应。444名参与者接受了鼻咽拭子中SARS-CoV-2核酸的多重RT-PCR检测或病毒特异性免疫球蛋白的血清学检测。报告了免疫后的不良事件(AEFI)。在第一次接种SARS-CoV-2两周后，82.5%的参与者抗SARS-CoV-2抗体的反应性超过了界值。3个月后，4名医务人员的鼻咽拭子检测呈阳性。超过四分之三的人报告了AEFI。我们的发现提供了关于疫苗接种3个月后的反应的洞察力，特别关注有效性数据，以及HCW接受者抱怨的AEFI的类型和数量。这项研究可作为未来研究的参考，以探索该疫苗的长期安全性，特别是在感染高危人群中，如卫生工作者。
This study investigated the response to BNT162b2 mRNA COVID-19 vaccine among healthcare workers (HCWs) in an Italian teaching hospital. 444 participants were surveyed with either multiple RT-PCR assays for detection of SARS-CoV-2 nucleic acid in nasopharyngeal swabs or serology testing for the research of virus-specific immunoglobulins. Adverse events following immunization (AEFI) were reported. Two weeks after the first dose anti-SARS-CoV-2 antibodies exceeded reactivity cut-off in 82.5% the participants. Four HCWs tested positive at nasopharyngeal swab after 3 months. More than three-quarters reported AEFIs. Our findings offer an insight regarding the vaccine response after 3 months from its administration, with a special focus on effectiveness data, as well as the type and number of AEFIs complained by HCW recipients. The presented study may serve as reference for future research which will be necessary to explore the long-term safety of this vaccine, especially in population at high risk for infection, such as HCWs.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1056/nejmoa2109072
发表时间：
2021-10-14
期刊：
The New England journal of medicine
影响因子：
--
作者：
Bergwerk M;Gonen T;Lustig Y;Amit S;Lipsitch M;Cohen C;Mandelboim M;Levin EG;Rubin C;Indenbaum V;Tal I;Zavitan M;Zuckerman N;Bar-Chaim A;Kreiss Y;Regev-Yochay G
通讯作者：
Regev-Yochay G
DOI：
10.3390/ijerph18052567
发表时间：
2021-03-04
影响因子：
--
作者：
Della Valle P;Fabbri M;Madotto F;Ferrara P;Cozzolino P;Calabretto E;D'Orso MI;Longhi E;Polosa R;Riva MA;Mazzaglia G;Sommese C;Mantovani LG;The Mustang-Occupation-Covid-Study Group
通讯作者：
The Mustang-Occupation-Covid-Study Group
DOI：
10.1016/j.cmi.2021.07.024
发表时间：
2021-12
期刊：
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
影响因子：
--
作者：
Buonfrate D;Piubelli C;Gobbi F;Martini D;Bertoli G;Ursini T;Moro L;Ronzoni N;Angheben A;Rodari P;Cardellino C;Tamarozzi F;Tais S;Rizzi E;Degani M;Deiana M;Prato M;Silva R;Bisoffi Z
通讯作者：
Bisoffi Z
影响因子：
5.5
作者：
Mateo-Urdiales A;Del Manso M;Andrianou X;Spuri M;D'Ancona F;Filia A;Rota MC;Petrone D;Vescio MF;Riccardo F;Bella A;Pezzotti P;Fabiani M
通讯作者：
Fabiani M